| Identification | Back Directory | [Name]
LY2228820 | [CAS]
862505-00-8 | [Synonyms]
Ralimetinib dimesylate
RALIMETINIB (LY2228820)
7-(2-tert-Butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-am
7-(2-tert-Butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-amine
5-[2-(1,1-Dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-amine
3H-Imidazo[4,5-b]pyridin-2-amine,5-[2-(1,1-dimethylethyl)-5-(4-fluorophenyl)-1H-imidazol-4-yl]-3-(2,2-dimethylpropyl)-
3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- | [Molecular Formula]
C24H29FN6 | [MDL Number]
MFCD17169991 | [MOL File]
862505-00-8.mol | [Molecular Weight]
420.53 |
| Hazard Information | Back Directory | [Uses]
Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc[1]. | [IC 50]
p38β MAPK: 3.2 nM (IC50); p38α MAPK: 5.3 nM (IC50) | [References]
[1] Campbell RM, et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol Cancer Ther. 2014 Feb;13(2):364-74. DOI:10.1158/1535-7163.MCT-13-0513 |
|
| Company Name: |
Wuhan Topule
|
| Telephone: |
+86-02787215551 19945035818 |
| Website: |
http://www.topule.com/ |
|